The successes of atezolizumab which is a monoclonal antibody-based immune checkpoint inhibitor (ICI) against programmed cell death- ligand 1 (PD-L1) have been achieved in various cancers such as non-small cell lung carcinoma, renal cell carcinoma, urothelial carcinoma [4]. This evidence concerns the gene CD274 and urothelial carcinoma.